Background The annual stroke rate in atrial fibrillation is around 5 per cent with increased risk in those with hypertension, diabetes, left ventricular dysfunction and other cardiovascular risk factors. This study set out to identify the patients with atrial fibrillation and modifiable risk factors for stroke.
Introduction
Atrial fibrillation (AF) is the commonest cardiac arrhythmia managed in primary care, 1 and because it is an important risk factor for stroke it has significant implications for people with the condition and for health services. 2 The prevalence of AF in general practice in England and Wales was estimated in 1998 at 12.1 per 1000 in men and 12.7 per 1000 in women with a reported increase in prevalence since 1994, 3 a similar increase has been reported in the USA. 4 Its prevalence increases with age, with approximately 5 per cent of those over 65, and 10 per cent of those over 85 years. 5, 6 The annual rate of stroke with AF is about 4.5 per cent. 7 There is consensus that the risk of stroke in people with AF is greater in those who also have hypertension, 8 diabetes, left ventricular dysfunction, or previous cerebrovascular accident and are older than 65. 9, 10 Other risk factors which may also contribute include: smoking, obesity, existing ischaemic heart disease and hyperlipidaemia, 11-13 although modifying these may result in a lesser reduction in stroke risk in people with AF. However they are worth addressing as many of these people are at risk from other cardiovascular diseases as well. 14 Anti-coagulation has been demonstrated to be effective in reducing the incidence of stroke in patients with AF, with aspirin providing lesser benefits. 15 Many believe that anti-coagulants are under-utilized, with only around a fifth of patients receiving them. 9, 16 One reason for this is the need to regulate Warfarin therapy strictly to avoid the risk of haemorrhage. Where this cannot be achieved in this elderly population then aspirin may provide a safer option; 17 though opting for aspirin ahead of Warfarin remains controversial. Decision making about this issue is often complex, because many with AF are elderly with multiple medical problems and therapy. 18, 19 In the UK Primary Care Trusts commission care for their geographical locality. One such trust was interested to examine the quality of care of patients with AF, and whether they could be identified by computer searches across a number of practices in their locality. If this proved feasible then this would allow these 1 patients to be identified, and services targeted appropriately. We therefore conducted this study to see if it was possible to identify high risk patients, with suboptimally managed AF, from searches of general practice computer records.
Method
This study was carried out in eight general practices, with a total registered population of 81 811 (range 3559 to 14 834), in a single locality in the south of England. There are similar numbers of very elderly, over 85 years. The AF prevalence is age-and sexstandardised against the England and Wales population. 20 The data were collected between May 2004 and July 2004, with written consent of the practices and approval of the local primary care trust. During this period a data collector visited each practice and collected information on demography, diagnosis, investigations, and treatment from their computer systems using the health query language MIQUEST 21 (Morbidity Information and Export Syntax; Box 1).
The data had to be extensively cleaned and processed. Data reliability was tested by careful examination of the denominator, the diagnostic and other clinical data due to be used in the study. 22, 23 This involved creating a graphical representation of the age-sex profile of each practice; and also for any diseases that were to be part of the analysis. Recording levels of numerical variables (e.g. systolic BP) were examined for, and histograms plotted to observe their distribution. Recording levels were compared between practices; and if there were large discrepancies in the data or missing data then the variable concerned has been excluded from the analysis. The only exceptions are ECG data and echocardiogram data, which are specifically included as examples where data quality is poor. Not all practice computer systems use precisely the same coding system. All these practices were either EMIS (Egton Medical Information Systems 24 ) or Torex Premiere. 25 Both of these use the Read version 2 5-Byte code set. However, EMIS uses many of its own codes; and has an entirely independent drug dictionary. The EMIS drug codes are unique and do not precisely mirror the Read classification for drugs. We recoded data into classes and preparations; so that we had a simple numeric variable which for example indicates whether a patient has been prescribed Warfarin.
We calculated the prevalence of AF and of cardiovascular co-morbidities and risk factors by age group and sex. We analysed in 10 year bands from age 25 upwards, grouping together the population over 85 years.
We went on to examine the proportion of people with AF who had one of the following cardiovascular conditions, ischaemic heart disease, heart failure and diagnosis of hypertension and the proportion of patients with cardiovascular risk factors (blood pressure, smoking status, BMI and cholesterol levels) recorded on the practice computer. In addition we identified those with mitral valve disease and rheumatic fever, and those treated with an anti-coagulant (Warfarin) and anti-platelet therapy (aspirin).
We defined current therapy as issue of a prescription in the last 60 days; as the locality policy was to issue repeat prescriptions for 60 days therapy, though locality representatives said that they often issued Warfarin prescriptions for shorter periods.
We then formulated audit criteria (Box 2) based best practice guidance; 26, 27 
Results
In total, there were 944 people with AF an overall prevalence of 11.5 per 1000 patients (Table 1 ) Prevalence rates increased with age, from less than 1 per 1000 in people aged under the age of 35 to 96.7 per 1000 in people aged over 75 years. The prevalence was higher in males than in females in all age categories, with an overall prevalence of 12.3 per 1000 males and 10.8 per 1000 females. 941 were aged 25 years and above, those aged below 25 years were excluded from the further analysis. The age-standardized prevalence, using the population of England and Wales, was 12.8 for males, 11.8 for females and 12.3 per 1000 overall. A high proportion of patients had a concurrent cardiovascular diagnoses ( Table 2 ). Ischaemic heart disease (IHD) was much more prevalent in men than women (31.6 per cent compared with 23.7 per cent); diabetes was more common in men (14.5 per cent compared with 11.6 per cent); stroke, heart failure and hypertension had smaller or no sex differences.
Cardiovascular risk factor recording was variable (Table 3) . Nearly everybody (98 per cent) had a blood pressure recording and just under 90 per cent a smoking record. BMI, cholesterol and LDL-cholesterol were recorded more in men. LDL was measured in less than half of men (43.1 per cent) and under a third of women (30.8 per cent).
Although the mean systolic and diastolic blood pressures, cholesterol and LDL cholesterol are below the target set for blood pressure control in national guidance 28 (Table 4) , this inevitably leaves a considerable proportion above. Fifty seven per cent have a blood pressure at or above the 140/ 85 threshold (i.e. either systolic is ≥140 or diastolic ≥85) of whom 28 per cent above 150/90 (Table 5 ). Approximately 10 per cent of men and women have cholesterol and LDL above recommended treatment thresholds; though these figures should be treated with caution because of the high percentage of patients who have not had a cholesterol or LDL measure. A total of 24.5 per cent are recorded as current or ex-smokers. Almost exactly twice as many men are smokers as women. Perhaps reflecting the relatively affluent area of Surrey these practices are located in, 63 per cent are recorded as having never smoked. Just over a quarter of people with AF have a BMI over 28. Only 9.5 per cent of people with AF are recorded as having an ECG, and only 4.5 per cent an echocardiogram. There is not sufficient data to make valid comments about left ventricular hypertrophy.
Anti-coagulant and anti-platelet therapy are prescribed differently to men and women. Warfarin is prescribed to more men than women (42.6 per cent, compared with 35.2 per cent). The peak age for using Warfarin is between 65 and 74 years (Table 6 ) Aspirin is currently prescribed less in men than women (28.2 and 34.5 per cent, respectively.) Aspirin prescribing increases as people with AF get older. It is used most in the very elderly of both sexes. Men have more contraindications to Warfarin and aspirin recorded than women. 453 of the 503 men (85.9 per cent) and 351 of 438 (80.1 per cent) of women diagnosed as having AF are receiving Warfarin or aspirin or have these drugs contraindicated. The calculation takes into account that 5 men and 6 women have contraindications to both Warfarin and aspirin, and that nine additional men and two women have a code that suggests they have been advised to purchase their own aspirin 'OTC' (over-the-counter direct from the pharmacist).
Control of the level of anti-coagulants is measured using INR with a target range of 2-3. The mean INR for men was 2.46, and for females 2.43. There was no difference in control of INR across the age groups or between genders. The range was from 1.0 to 5. Finally, we looked at high risk 26, 27 groups to see if more intensive treatment is being targeted at those most at risk. Warfarin and aspirin were prescribed in similar proportions to patients in the very high, high and moderate risk categories, with less prescribed to those at low risk. Men were prescribed more Warfarin that women, in all three of the highest risk categories. Hypertension, diabetes and heart failure were more prevalent in the high risk group; more so than in the very high risk group (people who had suffered a previous stroke or TIA.) These diseases were much less prevalent in those at moderate or low risk. A similar trend was seen in mean blood pressure.
Smoking was most prevalent in the low risk group (Table 7 )
Discussion

Principal findings
The study demonstrated that the use of Warfarin remains low, despite all the evidence of benefit, and guidelines produced for its use. Where Warfarin is used it is not targeted a those in the highest risk categories; though overall four out of five patients with AF are treated with Warfarin or aspirin or have contraindication to these therapies. The study showed the feasibility of using computer searches can be used to identify patients with AF; group them according to level or risk; and, identify those who are subopitmally managed. Practice computer data was excellent in some areas and variable in others. Nearly all patients with a diagnosis of AF have a record of their blood pressure, smoking habit and BMI; four out of five have had Warfarin or aspirin prescribed where it was not contraindicated. However, in others there is considerable scope for improvement in practice computer data; particularly the recording of ECG of echocardiograph evidence of left ventricular hypertrophy. We defined the prevalence of AF and how it differs between the sexes. In men it is at least double that in woman in every ten year age band up to age 75; after this age prevalence in women approximates to that in the male population. The overall prevalence in males and females is similar because there are many more women than men alive over age 75. Concurrent cardiovascular disease is much more common with advancing age.
Implications for practice
The existence of compelling evidence about the benefits of Warfarin is not translated into practice. The existence of evidencebased guidance alone is not enough to change practice. 18 The reasons why female appear to be prescribed aspirin less often and Warfarin more often need to be explored. Substantial numbers would benefit from improved blood pressure control, and possibly improved monitoring and management of hyperlipidaemia. Warfarin could be better targeted at those at greatest risk of stroke.
Limitations of the study
The study is based on routinely collected data, there was no additional input provided to promote data quality of consistency of recording between practices. We did not search the whole general practice record. Only structured, often referred to as 'Read coded' data, were used in the study. Narrative or 'free text' records, including text scanned into the computer system from hospital letters was not included. Similarly data still contained within any written records were not included.
There was inter-practice variation in data recording, and where levels of recording were lower than could be reasonably expected or there was marked variation between practices, those data were not included.
We relied on clinician entered codes that Warfarin was contraindicated, or that there was an adverse reaction; rather than following the example of Carroll and Majeed 6 and actively searching for data that identified that a contraindication was present. It was not possible to separate those patients who have paroxysmal AF, from those with persistent; nor was there consistent data recorded about cardioversion or carotid endarterectomy.
We acknowledged within our method that there are subtle variations between the different computer manufacturers' coding of data, and that we had to arbitrarily define what represented 'current' therapy.
Comparison with the literature
The age standardized prevalence of AF: 7.36 per cent in the over 65s, and 12.3 per cent in the over 85s (crude rates are 6 and 12 per cent) is higher than the 5 and 10 per cent reported elsewhere. 5, 6 Though similar to that reported in 1998. 3 The area from which the data in this study is collected is one of relatively high social class, something known to be associated with lower levels of cardiac morbidity. 29, 30 This data might indicate that the prevalence of AF is continuing to rise. 3, 4 This data shows much higher rates of anticoagulant use in routine clinical practice than in previous studies. It is roughly double the level (22 per cent) found by Deplanque et al., 16 and that (21 per cent) found by Wheeldon et al., 31 and Sudlow et al. 32 (23 per cent). Practice based, near patient anti-coagulant monitoring may contribute towards more patients to be treated with Warfarin. 33 The difference between male and female treatment rates might be that men are started on Warfarin in secondary care when treated for their heart disease or other cardiovascular morbidity at a younger age. People with AF would benefit from further reduction in blood pressure: 8 '. . . each 10 mmHg lower systolic BP is associated with a decrease in risk of stroke of approximately one third in subjects aged 60 to 79 years. The association is continuous down to levels of at least 115/75 mmHg. . . .'
Call for further research
Examination of the complete medical record, computerized and written, would allow the validity of these findings to be checked; there are well established methods to do this. 34, 35 The reasons for inter-practice variability in data need to be better understood; although reported for more than 10 years 36 they persist in many clinical areas. 37, 38 We need to know what type of intervention is likely to be successful in changing the behaviour of clinicians and ensure best practice is implemented. This might include use of: education, 37 telemedicine, 39 near patient testing, 33 financial incentives or other approach to improve the quality of care.
Conclusions
Usage of Warfarin remains low despite the existence of evidence and guidance for its use; though the practices involved in this study are achieving higher levels of anti-coagulant monitoring than previously reported. Use of Warfarin does not appear to be targeted at those at highest risk. Priorities for practices and localities should be: improved uptake of Warfarin for people with AF of high and very high risk of stroke; and, improved management of blood pressure. Automated searches of computer data have allowed subopitmally managed patients with AF to be identified; so that they can benefit from improved quality of care.
